Ipamorelin/CJC-1295 no-DAC is a blended GH secretagogue pair that users run primarily for recovery, sleep quality, and body composition, with community logs showing positive outcomes in roughly three-quarters of sleep-and-recovery reports and more than four-fifths of body-composition reports. Captured protocols are inconsistent on exact dose, but the modal cycle runs eight to twelve weeks continuously, most often injected pre-bedtime and sometimes morning or post-workout. The single clearest tradeoff is that the blend carries no FDA-approved indication, so all human use is off-label or compounded.

Research Evidence
Evidence shape
Clinical evidence for the Ipamorelin / CJC-1295 blend is nonexistent: zero registered trials, zero mapped indications, and no human results have been posted or completed. Breadth and quality are nil because no sponsor, academic or commercial, has ever advanced this specific combination through a formal clinical study. That vacuum is itself the signal: there are no withdrawn trials, thin indication files, or long-tail animal datasets; the record is entirely blank.
Anecdotal efficacy
Side effects
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
Price
price offers can be sorted by column
Dosing & Protocol
How Ipamorelin / CJC-1295 Blend is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
Peptide Deep Dive
Peptide Deep Dive is not projected for this peptide yet.
Peptide feedback
0 forum repliesLive community discussion for Ipamorelin / CJC-1295 Blend, shown here in the site layout and continued on the TVR forum.
No peptide feedback yet
Start the peptide feedback thread on the TVR forum.